ClinicalTrials.gg
CompletedNCT07044479Updated Sep 3, 2025

A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)

A Phase 1 interventional study of Enlicitide in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to learn what happens to enlicitide in a person's body over time when enlicitide is taken at the same time as coffee or tea. Researchers will measure the amount of enlicitide in the blood when taken with coffee or tea compared with enlicitide taken with water.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health
  • Is a non-smoker for at least 3 months prior to study entry
  • Part 1 only: Consumes at least 1 cup of caffeinated coffee per day
  • Part 2 only: Consumes at least 1 cup of caffeinated tea per day

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history or presence of medical or psychiatric condition or disease
  • History of gastrointestinal disease which might affect food and drug absorption, or has had gastric bypass or similar surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Enlicitide Coffee Sequence 1

    Participants will be randomized to receive enlicitide administered with water in period 1 and enlicitide with coffee in period 2.

    Drug: Enlicitide

  • Experimental
    Enlicitide Coffee Sequence 2

    Participants will be randomized to receive enlicitide administered with coffee in period 1 and enlicitide with water in period 2.

    Drug: Enlicitide

  • Experimental
    Enlicitide Tea Sequence 1

    Participants will be randomized to receive enlicitide administered with water in period 1 and enlicitide with tea in period 2.

    Drug: Enlicitide

  • Experimental
    Enlicitide Tea Sequence 2

    Participants will be randomized to receive enlicitide administered with tea in period 1 and enlicitide with water in period 2.

    Drug: Enlicitide

Interventions

  • Single dose of enlicitide is administered orally on day 1 of each testing period

    Also known as: MK-0616, enlicitide decanoate

06

What researchers measure

Primary outcomes

  1. Part 1-Coffee: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Enlicitide

    Blood samples will be collected to determine the AUC0-inf of enlicitide when administered with coffee

    Time frame: Predose and at designated time points up to 168 hours

  2. Part 1-Coffee: Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-last) of Enlicitide

    Blood samples will be collected to determine the AUC from time 0 to the time of last quantifiable sample of enlicitide when administered with coffee

    Time frame: Predose and at designated time points up to 168 hours

  3. Part 1 -Coffee : Maximum Plasma Concentration (Cmax) of Enlicitide

    Blood samples will be collected to determine the maximum observed drug concentration of enlicitide when administered with coffee

    Time frame: Predose and at designated time points up to 168 hours

  4. Part 2 -Tea: AUC0-last of Enlicitide

    Blood samples will be collected to determine the AUC from time 0 to the time of last quantifiable sample of enlicitide when administered with tea

    Time frame: Predose and at designated time points up to 168 hours

  5. Part 2 - Tea: AUC0-Inf of Enlicitide

    Blood samples will be collected to determine the AUC0-inf of enlicitide when administered with tea.

    Time frame: Predose and at designated time points up to 168 hours

  6. Part 2 -Tea: Cmax of Enlicitide

    Blood samples will be collected to determine the maximum observed drug concentration of enlicitide when administered with tea

    Time frame: Predose and at designated time points up to 168 hours

Secondary outcomes

  1. Part 1 - Coffee: Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 7 weeks

  2. Part 2 - Tea: Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 7 weeks

  3. Part 1 - Coffee: Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 7 weeks

  4. Part 2 - Tea: Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 7 weeks

07

Study locations

1 site
  • Celerion, Inc. ( Site 0001)
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Aug 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 1, 2025
StartActual
Jul 3, 2025
Primary completionActual
Aug 13, 2025
CompletionActual
Aug 28, 2025
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07044479
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
Jul 3, 2025
Primary completion
Aug 13, 2025
Completion
Aug 28, 2025
Last update
Sep 3, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlicitide

Start the discussion